• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

革兰氏阴性杆菌菌血症患者中,每8小时静脉注射400毫克环丙沙星与每12小时静脉注射400毫克环丙沙星的药代动力学/药效学比较研究。

Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.

作者信息

Saengsuwan Phanvasri, Jaruratanasirikul Sutep, Jullangkoon Monchana, Aeinlang Nanchanit

机构信息

Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.

出版信息

J Med Assoc Thai. 2010 Jul;93(7):784-8.

PMID:20649056
Abstract

OBJECTIVE

To compare the ratio of the area under the concentration-time curve at 24 hours to the minimum inhibitory concentration value (24-h AUC/MIC) of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h.

MATERIAL AND METHOD

A prospective, randomized, two-way crossover study of 10 patients with gram-negative bacilli bacteremia was conducted. All patients were randomized to receive ciprofloxacin in both regimens consecutively: (i) 400 mg intravenously every 8 h for four doses; (ii) 400 mg intravenously every 12 h for four doses. Ciprofloxacin pharmacokinetic studies were carried out after the start of both regimens.

RESULTS

For the ciprofloxacin 400 mg intravenously every 8 h regimen, the 24-h AUC/MIC at MICs of 0.5 and 1 microg/ml were 218.63 +/- 78.75 and 109.31 +/- 39.37, respectively. For the ciprofloxacin 400 mg intravenously every 12 h regimen, the 24-h AUC/MIC at MICs of 0.5 and +/- microg/ml were 144.07 +/- 57.02 and 72.03 +/- 28.51, respectively. After 14 days of ciprofloxacin treatment, the gram-negative bacilli infections were eradicated in all patients. Moreover, during both regimens, no adverse events related to the use of ciprofloxacin were observed.

CONCLUSION

Both ciprofloxacin 400 mg every 8 h and 400 mg every 12 h regimens can provide good coverage for pathogens with the susceptibility breakpoint of ciprofloxacin with an MIC of 0.5 microg/ml. For pathogens with an MIC of 1.0 microg/ml, only ciprofloxacin 400 mg every 8 h regimen can provide a 24-h AUC/MIC ratio greater than 100.

摘要

目的

比较每8小时静脉注射400mg环丙沙星与每12小时静脉注射400mg环丙沙星的24小时血药浓度-时间曲线下面积与最低抑菌浓度值之比(24小时AUC/MIC)。

材料与方法

对10例革兰氏阴性杆菌血症患者进行了一项前瞻性、随机、双向交叉研究。所有患者均随机连续接受两种方案的环丙沙星治疗:(i)每8小时静脉注射400mg,共四剂;(ii)每12小时静脉注射400mg,共四剂。两种方案开始后均进行环丙沙星药代动力学研究。

结果

对于每8小时静脉注射400mg环丙沙星方案,在最低抑菌浓度为0.5和1μg/ml时,24小时AUC/MIC分别为218.63±78.75和109.31±39.37。对于每12小时静脉注射400mg环丙沙星方案,在最低抑菌浓度为0.5和±μg/ml时,24小时AUC/MIC分别为144.07±57.02和72.03±28.51。环丙沙星治疗14天后,所有患者的革兰氏阴性杆菌感染均得到根除。此外,在两种方案治疗期间,均未观察到与使用环丙沙星相关的不良事件。

结论

每8小时400mg和每12小时400mg的环丙沙星方案均可为最低抑菌浓度为0.5μg/ml的环丙沙星敏感病原体提供良好的覆盖。对于最低抑菌浓度为1.0μg/ml的病原体,只有每8小时400mg环丙沙星方案可提供大于100的24小时AUC/MIC比值。

相似文献

1
Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.革兰氏阴性杆菌菌血症患者中,每8小时静脉注射400毫克环丙沙星与每12小时静脉注射400毫克环丙沙星的药代动力学/药效学比较研究。
J Med Assoc Thai. 2010 Jul;93(7):784-8.
2
Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.群体药代动力学及应用蒙特卡洛模拟评估目前推荐的囊性纤维化成年患者环丙沙星给药方案
Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73. doi: 10.1128/AAC.45.12.3468-3473.2001.
3
Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.革兰氏阴性杆菌菌血症患者中头孢吡肟持续输注与间歇给药的比较。
J Pharm Pharmacol. 2002 Dec;54(12):1693-6. doi: 10.1211/002235702171.
4
Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.支持提高环丙沙星 AUC24/MIC 目标值以治疗肠杆菌科血流感染。
J Antimicrob Chemother. 2010 Aug;65(8):1725-32. doi: 10.1093/jac/dkq211. Epub 2010 Jun 17.
5
Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers.
J Clin Pharmacol. 2005 Nov;45(11):1236-44. doi: 10.1177/0091270005280542.
6
Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.新型氟喹诺酮类药物ABT492与环丙沙星在体外动态模型中对大肠杆菌和铜绿假单胞菌的比较药效学
Int J Antimicrob Agents. 2004 Aug;24(2):173-7. doi: 10.1016/j.ijantimicag.2004.02.026.
7
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.应用蒙特卡罗模拟和来自住院患者的稳态药代动力学数据比较哌拉西林/他唑巴坦间歇性和持续输注的药效动力学。
Ann Pharmacother. 2009 Nov;43(11):1747-54. doi: 10.1345/aph.1M304. Epub 2009 Oct 6.
8
Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.利用健康志愿者的药代动力学数据和2002年的最低抑菌浓度数据,对环丙沙星和左氧氟沙星针对铜绿假单胞菌的药效学进行模拟比较。
Clin Ther. 2007 Jul;29(7):1421-7. doi: 10.1016/j.clinthera.2007.07.024.
9
Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.危重症患者的环丙沙星药代动力学:一项前瞻性队列研究。
J Crit Care. 2008 Sep;23(3):422-30. doi: 10.1016/j.jcrc.2007.11.011. Epub 2008 Apr 18.
10
Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats.环丙沙星单次静脉注射及多次口服给药后在猫体内的药代动力学
J Vet Pharmacol Ther. 2004 Jun;27(3):155-62. doi: 10.1111/j.1365-2885.2004.00573.x.